

CHAD THERAPEUTICS INC

Form DEFA14A

January 18, 2008

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 14A INFORMATION  
Proxy Statement Pursuant to Section 14(a) of the Securities  
Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

CHAD Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

N/A

(2) Aggregate number of securities to which transaction applies:

N/A

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

N/A

(4) Proposed maximum aggregate value of transaction:

N/A

(5) Total fee paid:

N/A

- o Fee paid previously with preliminary materials.
- o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

N/A

(2) Form, Schedule or Registration Statement No.:

N/A

(3) Filing Party:

N/A

(4) Date Filed:

N/A

---

January 18, 2008

**The Special Meeting of CHAD Shareholders is only a short time away.**

**Your Vote FOR the Asset Sale is critical to CHAD's future.**

**Please vote today by proxy card, toll free telephone or internet.**

Dear Fellow CHAD Shareholder:

In our proxy material previously sent to you we have explained why the proposed sale of CHAD's oxygen conserver business to Inovo, Inc. for approximately \$5.25 million in cash is critical to the future of the Company and in the best interests of our shareholders. The Asset Sale is to be voted on at the Special Meeting of CHAD Shareholders. Please note that the meeting will be held on **Thursday, January 31<sup>st</sup>**.

According to our records we have not yet received your vote for the Special Meeting.

**Please take the time to vote FOR the Asset Sale today. Since time is short, we urge you to follow the instructions enclosed that provide for voting by internet or toll-free telephone.** You may also vote by signing and returning the enclosed proxy card. Please make certain that you mail your card in time so that it is received prior to the January 31<sup>st</sup> Special Meeting.

If you have already voted, please accept our thanks. You need take no further action at this time.

**Your Support is Urgently Needed NOW!**

Our oxygen therapy business is currently unprofitable and generates a significant negative cash flow from operations. We do not currently have the capital resources to fund continuing losses in the oxygen therapy business. **Failure by shareholders to approve the asset sale could result in an orderly winding down of our operations or the Company seeking protection under federal bankruptcy laws.**

The sale of our oxygen conserver business is the first step in our planned exit from the oxygen therapy business; we are actively pursuing the possible sale of our transfilling business. **Once we have exited the oxygen therapy business, we will devote all our efforts to the development and commercialization of products for the sleep disorder market.** Such efforts will likely require us to obtain additional funding and/or to enter into strategic partnerships with other companies who could facilitate the commercialization of our sleep disorder products. We believe our ability to pursue such opportunities will be significantly enhanced once we have exited the oxygen therapy business.

A number of investors and potential strategic partners have indicated a preliminary interest in our sleep disorder products; however, their interest in investing or partnering with us has been constrained by the continuing operating losses suffered in our oxygen therapy business and the fact that all of the assets related to the sleep disorder market are pledged as collateral on our secured credit line. **If the Asset Sale is approved, we will use the proceeds from such sale to pay all of our outstanding secured debt, including the credit line, thereby enabling us to pursue our strategy for the sleep disorder market.**

-over-

For those holders in street-name, your brokerage firm or bank will not vote your shares on the proposed Asset Sale without your specific instructions. **Therefore please follow the internet or toll-free telephone voting instructions provided by your broker or bank in order to make certain that your shares are counted for the special meeting.** You may also vote by signing and returning the enclosed proxy card, provided that it is received prior to the Special Meeting.

**Approval of the Asset Sale requires the affirmative vote of holders of at least a majority of the outstanding shares of CHAD common stock. Failure to vote is the equivalent of a No vote. Please vote your shares FOR the Asset Sale today.**

If you need assistance in voting your shares, please contact our proxy solicitor, Morrow & Co., LLC at (800) 607-0088.

Thank you for your cooperation and continued support.

Very truly yours,

Thomas E. Jones  
Chairman of the Board  
Enclosures

Earl L. Yager  
President & Chief Executive Officer